The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | Tirabrutinib and entospletinib or idelalisib with or without obinutuzumab in R/R CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, gives an update on the Phase II CLLRUmbrella2 trial (NCT02983617) in which patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) were given a combinational treatment regime of tirabrutinib and entospletinib or idelalisib with or without obinutuzumab. Dr Eichhorst explains that some important study endpoints, including complete response (CR) rate and undetectable measurable residual disease (MRD) were not achieved, and in addition, the study reported high adverse effects rates. Dr Eichhorst further mentions how future combinational therapies for CLL should combine agents targeting different pathways such as the BTK and BCL-2 signaling pathways. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
